Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol

M. R. Liebowitz, J. M. Gorman, A. J. Fyer, R. Campeas, A. P. Levin, D. Sandberg, Eric Hollander, L. Papp, D. Goetz

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Forty-one patients meeting DSM-III criteria for social phobia completed a randomized comparative trial of the monoamine oxidase inhibitor phenelzine, the cardioselective β-adrenergic blocker atenolol, and placebo. No significant differences were seen after 4 weeks of treatment in this preliminary trial. At the end of 8 weeks, however, phenelzine demonstrated greater efficacy than atenolol or placebo on dimensional ratings of overall severity of social phobia. No atenolol-placebo differences were observed. The authors shall present maintenance and discontinuation findings in a final report. Phenelzine may act in patients with social phobia by directly reducing interpersonal hypersensitivity.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalJournal of Clinical Psychiatry
Volume49
Issue number7
StatePublished - 1988
Externally publishedYes

Fingerprint

Phenelzine
Atenolol
Placebos
Drug Therapy
Adrenergic Antagonists
Monoamine Oxidase Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Hypersensitivity
Maintenance
Social Phobia
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Liebowitz, M. R., Gorman, J. M., Fyer, A. J., Campeas, R., Levin, A. P., Sandberg, D., ... Goetz, D. (1988). Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry, 49(7), 252-257.

Pharmacotherapy of social phobia : An interim report of a placebo-controlled comparison of phenelzine and atenolol. / Liebowitz, M. R.; Gorman, J. M.; Fyer, A. J.; Campeas, R.; Levin, A. P.; Sandberg, D.; Hollander, Eric; Papp, L.; Goetz, D.

In: Journal of Clinical Psychiatry, Vol. 49, No. 7, 1988, p. 252-257.

Research output: Contribution to journalArticle

Liebowitz, MR, Gorman, JM, Fyer, AJ, Campeas, R, Levin, AP, Sandberg, D, Hollander, E, Papp, L & Goetz, D 1988, 'Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol', Journal of Clinical Psychiatry, vol. 49, no. 7, pp. 252-257.
Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D et al. Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry. 1988;49(7):252-257.
Liebowitz, M. R. ; Gorman, J. M. ; Fyer, A. J. ; Campeas, R. ; Levin, A. P. ; Sandberg, D. ; Hollander, Eric ; Papp, L. ; Goetz, D. / Pharmacotherapy of social phobia : An interim report of a placebo-controlled comparison of phenelzine and atenolol. In: Journal of Clinical Psychiatry. 1988 ; Vol. 49, No. 7. pp. 252-257.
@article{637ddfbb590a4f7f87e28c8c65358f71,
title = "Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol",
abstract = "Forty-one patients meeting DSM-III criteria for social phobia completed a randomized comparative trial of the monoamine oxidase inhibitor phenelzine, the cardioselective β-adrenergic blocker atenolol, and placebo. No significant differences were seen after 4 weeks of treatment in this preliminary trial. At the end of 8 weeks, however, phenelzine demonstrated greater efficacy than atenolol or placebo on dimensional ratings of overall severity of social phobia. No atenolol-placebo differences were observed. The authors shall present maintenance and discontinuation findings in a final report. Phenelzine may act in patients with social phobia by directly reducing interpersonal hypersensitivity.",
author = "Liebowitz, {M. R.} and Gorman, {J. M.} and Fyer, {A. J.} and R. Campeas and Levin, {A. P.} and D. Sandberg and Eric Hollander and L. Papp and D. Goetz",
year = "1988",
language = "English (US)",
volume = "49",
pages = "252--257",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacotherapy of social phobia

T2 - An interim report of a placebo-controlled comparison of phenelzine and atenolol

AU - Liebowitz, M. R.

AU - Gorman, J. M.

AU - Fyer, A. J.

AU - Campeas, R.

AU - Levin, A. P.

AU - Sandberg, D.

AU - Hollander, Eric

AU - Papp, L.

AU - Goetz, D.

PY - 1988

Y1 - 1988

N2 - Forty-one patients meeting DSM-III criteria for social phobia completed a randomized comparative trial of the monoamine oxidase inhibitor phenelzine, the cardioselective β-adrenergic blocker atenolol, and placebo. No significant differences were seen after 4 weeks of treatment in this preliminary trial. At the end of 8 weeks, however, phenelzine demonstrated greater efficacy than atenolol or placebo on dimensional ratings of overall severity of social phobia. No atenolol-placebo differences were observed. The authors shall present maintenance and discontinuation findings in a final report. Phenelzine may act in patients with social phobia by directly reducing interpersonal hypersensitivity.

AB - Forty-one patients meeting DSM-III criteria for social phobia completed a randomized comparative trial of the monoamine oxidase inhibitor phenelzine, the cardioselective β-adrenergic blocker atenolol, and placebo. No significant differences were seen after 4 weeks of treatment in this preliminary trial. At the end of 8 weeks, however, phenelzine demonstrated greater efficacy than atenolol or placebo on dimensional ratings of overall severity of social phobia. No atenolol-placebo differences were observed. The authors shall present maintenance and discontinuation findings in a final report. Phenelzine may act in patients with social phobia by directly reducing interpersonal hypersensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0023758571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023758571&partnerID=8YFLogxK

M3 - Article

C2 - 3292516

AN - SCOPUS:0023758571

VL - 49

SP - 252

EP - 257

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7

ER -